[go: up one dir, main page]

RU2007141588A - Наночастица, и на ее основе инфузионный раствор и фармацевтическая композици - Google Patents

Наночастица, и на ее основе инфузионный раствор и фармацевтическая композици Download PDF

Info

Publication number
RU2007141588A
RU2007141588A RU2007141588/15A RU2007141588A RU2007141588A RU 2007141588 A RU2007141588 A RU 2007141588A RU 2007141588/15 A RU2007141588/15 A RU 2007141588/15A RU 2007141588 A RU2007141588 A RU 2007141588A RU 2007141588 A RU2007141588 A RU 2007141588A
Authority
RU
Russia
Prior art keywords
nanoparticle according
active substance
therapeutically active
nanoparticle
rna
Prior art date
Application number
RU2007141588/15A
Other languages
English (en)
Other versions
RU2490027C9 (ru
RU2490027C2 (ru
Inventor
Норберт ВАЛДЭФНЕР (DE)
Норберт ВАЛДЭФНЕР
Клаус ДЭКЕН (DE)
Клаус ДЭКЕН
Андреас ЙОРДАН (DE)
Андреас ЙОРДАН
Регина ШОЛЬЦ (DE)
Регина ШОЛЬЦ
Original Assignee
МэджФос Нанотекнолэджиз АГ (DE)
МэджФос Нанотекнолэджиз АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МэджФос Нанотекнолэджиз АГ (DE), МэджФос Нанотекнолэджиз АГ filed Critical МэджФос Нанотекнолэджиз АГ (DE)
Publication of RU2007141588A publication Critical patent/RU2007141588A/ru
Application granted granted Critical
Publication of RU2490027C2 publication Critical patent/RU2490027C2/ru
Publication of RU2490027C9 publication Critical patent/RU2490027C9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1. Наночастица, связанная с по меньшей мере одним терапевтически активным веществом посредством линкера, содержащего группу, которая является термолабильной, электромагнитно лабильной, фотолабильной, кислотно-лабильной или может интеркалироваться или расщепляться энзиматически, причем освобождение терапевтически активного вещества от наночастицы вызывается, или инициируется, или существенно ускоряется переменным магнитным полем. ! 2. Наночастица по п.1, которая связана с терапевтически активным веществом ковалентной связью. ! 3. Наночастица по п.1, которая связана с терапевтически активным веществом посредством линкера, выбранного из группы, включающей молекулу нуклеиновой кислоты, полипептид, пептидную нуклеиновую кислоту, аптамер, ДНК, РНК, лейфиновый зиппер, олигонуклеотид, олигопептид, биотин, авидин, стептавидин, связь гаптен-антитело или связь биотин-авидин. ! 4. Наночастица по п.1, которая связана посредством линкера, выбранного из группы, включающей конструкцию двуцепочечной нуклеиновой кислоты, двойную спираль, гомо-гибрид или гетеро-гибрид типа ДНК-ДНК, ДНК-РНК, ДНК-ПНК, РНК-РНК, РНК-ПНК или ПНК-ПНК. ! 5. Наночастица по пп.1-4, которая имеет защитную оболочку или покрытие. ! 6. Наночастица по п.5, в которой защитная оболочка или покрытие имеет аминогруппы или карбоксильные группы. ! 7. Наночастица по п.1 или 2, которая связана с терапевтически активным веществом, выбранным из группы, включающей антипролиферативные, антимиграционные, антиангиогенные, противотромбозные, противовоспалительные, цитостатики, цитотоксические, антикоагуляционные, антибактериальные, антивирусные и/или противогрибковые препараты. !

Claims (14)

1. Наночастица, связанная с по меньшей мере одним терапевтически активным веществом посредством линкера, содержащего группу, которая является термолабильной, электромагнитно лабильной, фотолабильной, кислотно-лабильной или может интеркалироваться или расщепляться энзиматически, причем освобождение терапевтически активного вещества от наночастицы вызывается, или инициируется, или существенно ускоряется переменным магнитным полем.
2. Наночастица по п.1, которая связана с терапевтически активным веществом ковалентной связью.
3. Наночастица по п.1, которая связана с терапевтически активным веществом посредством линкера, выбранного из группы, включающей молекулу нуклеиновой кислоты, полипептид, пептидную нуклеиновую кислоту, аптамер, ДНК, РНК, лейфиновый зиппер, олигонуклеотид, олигопептид, биотин, авидин, стептавидин, связь гаптен-антитело или связь биотин-авидин.
4. Наночастица по п.1, которая связана посредством линкера, выбранного из группы, включающей конструкцию двуцепочечной нуклеиновой кислоты, двойную спираль, гомо-гибрид или гетеро-гибрид типа ДНК-ДНК, ДНК-РНК, ДНК-ПНК, РНК-РНК, РНК-ПНК или ПНК-ПНК.
5. Наночастица по пп.1-4, которая имеет защитную оболочку или покрытие.
6. Наночастица по п.5, в которой защитная оболочка или покрытие имеет аминогруппы или карбоксильные группы.
7. Наночастица по п.1 или 2, которая связана с терапевтически активным веществом, выбранным из группы, включающей антипролиферативные, антимиграционные, антиангиогенные, противотромбозные, противовоспалительные, цитостатики, цитотоксические, антикоагуляционные, антибактериальные, антивирусные и/или противогрибковые препараты.
8. Наночастица по п.7, которая связана с терапевтически активным веществом, выбранным из группы, включающей актиномицин D, аметантрон, 9-аминокамфотецин, аминоглутетимид, амсакрин, анастрозол, антагонисты пуриновых и пиримидиновых оснований, антрациклины, ингибиторы ароматазы, аспарагиназу, антиэстрогены, бендамустин, бексаротен, биолимус А9, блеомицин, бузерелин, бусульфан, калихеамицины, камптотецин, производные камптотецина, капецитабин, карбоплатин, кармустин, хлорамбуцил, цисплатин, кладрибин, циклофосфамид, цитарабин, цитозинарабинозид, ал килирующие цитостатики, дакарбазин, да ктиномицин, даунорубицин, 5'-деокси-5-фторуридин, доцетаксел, доксорубицин (адриамицин), доксорубицин липо, эпирубицин, эстрамустин, этопозид, эксеместан, флударабин, фтороурацил, антагонисты фолиевой кислоты, форместан, гемцитабин, глюкокортикоиды, гозерелин, гормоны и гормональные антагонисты, гикамтин, гидроксимочевина, идарубицин, ифосфамид, иматиниб, иринотекан, детрозол, левпрорелин, ломустин, майтанзиноиды, мелфалан, меркаптопурин, метотрексат, милтефозин, митомицины, митоподозид, антимитотические агенты, митоксантрон, нимустин, оксалиплатин, оксазафосфорины, паклитаксел, пентостатин, производные подофиллотоксина, прокарбазин, рапамицин, родомицин D, тамоксифен, темозоломид, тенипозид, тестолактон, тиотепа, тиогуанин, ингибиторы топоизомеразы, топотекан, треосульфан, третиноин, трипторелин, трофосфамиды, алкалоиды барвинка, винбластин, винкристин, виндезин, винорелбин, цитостатически активные антибиотики.
9. Наночастица по п.7, которая связана с терапевтически активным веществом, выбранным из группы, включающей нуклеиновые кислоты, аминокислоты, пептиды, протеины, углеводы, липиды, гликопротеины, гликаны или липопротеины, причем вышеуказанные вещества имеют антипролиферативные, антимиграционные, антиангиогенные, противотромбозные, противовоспалительные, цитостатические, цитотоксические, антикоагуляционные, антибактериальные, антивирусные и/или противогрибковые свойства.
10. Наночастица по п.1 или 2, которая состоит из суперпарамагнитных оксидов железа или из чистого железа, имеющего оксидный слой.
11. Наночастица по п.1 или 2, которая связана с сенсибилизатором, радиосенсибилизатором и/или усилителем в качестве дополнения к обычным способам лечения рака.
12. Наночастица по п.1 или 2, которая связана своей поверхностью с моноклональными антителами или соответственно фрагментами антител и/или аптамеров.
13. Инфузионный раствор, содержащий наночастицы по пп.1-12.
14. Применение наночастиц по пп.1-12 в качестве компонента для приготовления фармацевтической композиции для лечения и/или профилактики пролиферативных заболеваний, рака и бактериальных инфекций.
RU2007141588/15A 2005-04-12 2006-04-12 Магнитная наночастица для лечения и/или профилактики рака, на ее основе инфузионный раствор и фармацевтическая композиция RU2490027C9 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102005016873.6 2005-04-12
DE102005016873A DE102005016873A1 (de) 2005-04-12 2005-04-12 Nanopartikel-Wirstoff-Konjugate
US67510005P 2005-04-27 2005-04-27
US60/675,100 2005-04-27
PCT/DE2006/000653 WO2006108405A2 (de) 2005-04-12 2006-04-12 Nanopartikel-wirkstoff-konjugate

Publications (3)

Publication Number Publication Date
RU2007141588A true RU2007141588A (ru) 2009-05-20
RU2490027C2 RU2490027C2 (ru) 2013-08-20
RU2490027C9 RU2490027C9 (ru) 2013-09-27

Family

ID=37055300

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007141588/15A RU2490027C9 (ru) 2005-04-12 2006-04-12 Магнитная наночастица для лечения и/или профилактики рака, на ее основе инфузионный раствор и фармацевтическая композиция

Country Status (17)

Country Link
US (1) US9345768B2 (ru)
EP (1) EP1871423B9 (ru)
JP (1) JP5037490B2 (ru)
KR (3) KR20130098441A (ru)
CN (1) CN101247836B (ru)
AU (1) AU2006233483B2 (ru)
BR (1) BRPI0610220A2 (ru)
CA (1) CA2603734C (ru)
DE (2) DE102005016873A1 (ru)
DK (1) DK1871423T3 (ru)
ES (1) ES2392346T3 (ru)
IL (1) IL186521A (ru)
MX (1) MX2007012670A (ru)
NZ (1) NZ561928A (ru)
RU (1) RU2490027C9 (ru)
WO (1) WO2006108405A2 (ru)
ZA (1) ZA200708692B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2431472C2 (ru) * 2009-09-24 2011-10-20 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации Способ получения наночастиц магнетита, стабилизированных биосовместимым полимером, имеющим функциональные формильные группы

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
EP1919507A2 (en) * 2005-08-04 2008-05-14 Thomas William Rademacher Nanoparticles comprising antibacterial ligands
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
CA2651763A1 (en) * 2006-05-17 2007-11-29 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of T He University Of Nevada Magnetorheological fluids and therapeutic uses thereof
US8466154B2 (en) 2006-10-27 2013-06-18 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
US20080213377A1 (en) * 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
CA2671806A1 (en) * 2006-12-08 2008-06-19 Austin M. Derfus Remotely triggered release from heatable surfaces
BRPI0808635B1 (pt) * 2007-03-07 2022-06-07 Abraxis Bioscience, Llc Uso de uma composição farmacêutica compreendendo nanopartículas que compreendem rapamicina ou um seu derivado e uma proteína veículo, composição para uso em um método de tratamento de câncer em um indivíduo, forma de dosagem unitária para o referido tratamento, e kit
DE102007011702A1 (de) * 2007-03-08 2008-09-11 Rheinische Friedrich-Wilhelms Universität Aptamer-basierte Reagenzien
KR101010100B1 (ko) 2007-06-28 2011-01-24 (주)미래생명공학연구소 나노 입자를 이용한 유전자도입 배아 줄기세포의 제조 방법
DE102008003615A1 (de) 2008-01-09 2009-07-16 Magforce Nanotechnologies Ag Magnetische Transducer
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
US8236284B1 (en) 2008-04-02 2012-08-07 University Of Central Florida Research Foundation, Inc. Multimodal, multifunctional polymer coated nanoparticles
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
JP5526324B2 (ja) * 2008-07-15 2014-06-18 独立行政法人物質・材料研究機構 薬物が結合可能な光応答性薬物輸送体
AU2008361497B2 (en) * 2008-09-04 2014-07-17 Takeshi Kobayashi Methods and kits for hyperthermia and CTLA4 inhibitory therapy
MX2011002847A (es) * 2008-09-19 2011-04-07 Activus Pharma Co Ltd Polvo de compuesto organico combinado para uso medico y metodo de produccion y suspension del mismo.
EP2189539B2 (en) * 2008-11-21 2018-06-13 Chimera Biotec GmbH Conjugate complexes for analyte detection
ES2381022T3 (es) * 2008-12-19 2012-05-22 Biolitec Ag Nanopartículas de fosfato de calcio como vehículo de colorantes para la terapia fotodinámica
WO2010074675A1 (en) * 2008-12-23 2010-07-01 Board Of Regents Of The University Of Texas System Inflammation targeting particles
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20100294952A1 (en) * 2009-01-15 2010-11-25 Northwestern University Controlled agent release and sequestration
WO2010091183A2 (en) * 2009-02-04 2010-08-12 The Regents Of The University Of Colorado, A Body Corporate Non-invasive detection of complement-mediated inflammation using cr2-targeted nanoparticles
US8911766B2 (en) * 2009-06-26 2014-12-16 Abbott Cardiovascular Systems Inc. Drug delivery compositions including nanoshells for triggered drug release
EP2490723A1 (en) * 2009-10-19 2012-08-29 University Of Louisville Research Foundation, Inc. Nanoparticles for drug delivery
ES2600229T3 (es) * 2009-11-12 2017-02-07 Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH Nanopartículas magnéticas biocompatibles para el tratamiento de glioblastomas
ES2539588T3 (es) 2009-11-18 2015-07-02 Nanobacterie Tratamiento de cáncer o tumor inducido por la liberación de calor generado por diversas cadenas de magnetosomas extraídas de bacterias magnetotácticas y sometidas a un campo magnético alterno
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
US8226985B2 (en) 2010-01-28 2012-07-24 International Business Machines Corporation Surface modified nanoparticles, methods of their preparation, and uses thereof for gene and drug delivery
US20110206611A1 (en) * 2010-02-24 2011-08-25 Genisphere, Llc DNA Dendrimers as Thermal Ablation Devices
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
CA2816121C (en) 2010-11-01 2017-06-13 Syracuse University System and method for delivery of dna-binding chemotherapy drugs using nanoparticles
EP2646818A4 (en) * 2010-11-30 2016-09-21 Univ Illinois SILICANANOPARTIKELKONJUGATE
CA2828255A1 (en) 2011-02-25 2012-08-30 South Dakota State University Protein nanocarriers for topical delivery
CA2828253C (en) 2011-02-25 2016-10-18 South Dakota State University Polymer conjugated protein micelles
RU2568344C2 (ru) 2011-03-10 2015-11-20 Магфорс Аг Компьютеризованное средство имитационного моделирования для предоставления помощи в планировании термотерапии
FR2974815B1 (fr) 2011-05-06 2014-01-10 Univ Paris Curie Utilisation d'au moins un agent chelatant introduit dans le milieu de culture de bacteries magnetotactiques pour stimuler la croissance de ces bacteries
US9408912B2 (en) 2011-08-10 2016-08-09 Magforce Ag Agglomerating magnetic alkoxysilane-coated nanoparticles
DE102011112898A1 (de) * 2011-09-08 2013-03-14 Charité - Universitätsmedizin Berlin Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen
KR101337684B1 (ko) 2011-10-17 2013-12-30 성균관대학교산학협력단 표적지향 및 치료가 가능한 다기능성 핵산 기반 항암제, 이의 제조 방법 및 이를 포함하는 항암제 조성물
CN102539760A (zh) * 2012-02-11 2012-07-04 刘�东 具有体外肿瘤靶向作用的经叶酸配体修饰的氧化铁纳米颗粒与其制备方法及体外评价方法
US9393306B2 (en) 2012-04-24 2016-07-19 The Board Of Regents Of The University Of Oklahoma Singlet oxygen-labile linkers and methods of production and use thereof
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
JP6433896B2 (ja) 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 組織再生のためのエキソソームおよびマイクロリボ核酸
WO2014107419A1 (en) * 2013-01-02 2014-07-10 The Johns Hopkins University Use of oscillating gradients of high magnetic field for specific destruction of cells labeled with magnetic nanoparticles
WO2014124329A1 (en) 2013-02-08 2014-08-14 University Of Louisville Research Foundation, Inc. Nanoparticles for drug delivery
HK1220888A1 (zh) * 2013-03-15 2017-05-19 Georgia State University Research Foundation, Inc. 用於将治疗剂和显像剂递送至窦和中耳的组合物和方法
KR101465626B1 (ko) * 2013-05-23 2014-12-10 고려대학교 산학협력단 바이오틴을 포함하는 표적 특이적 항암 약물 전구체
RU2550955C1 (ru) * 2013-12-11 2015-05-20 Общество с ограниченной ответственностью "Уральский центр биофармацевтических технологий Способ электрохимического иммуноанализа для определения вирусов/антигенов вирусов
US10464955B2 (en) * 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
RU2563369C1 (ru) * 2014-02-28 2015-09-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ ферримагнито-термохимиотерапии злокачественных опухолей комбинациями магнитоуправляемых нанопрепаратов с визуализацией онкогенеза, определением терапии, предпочтительной в режиме реального времени, и мониторингом результатов лечения в эксперименте
RU2561294C1 (ru) * 2014-05-08 2015-08-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ торможения роста лимфосаркомы плисса в эксперименте
ES2725948T3 (es) 2014-06-04 2019-09-30 Exicure Inc Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas
RU2581946C2 (ru) * 2014-07-10 2016-04-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения рака мочевого пузыря
JP6878274B2 (ja) 2014-10-03 2021-05-26 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム
EP3310342A4 (en) * 2015-06-16 2019-03-06 The Trustees of the University of Pennsylvania INORGANIC RETARD PARTICLES WITH FAST ACTIVE LOAD
US11260027B2 (en) 2015-07-29 2022-03-01 Musc Foundation For Research Development Donor organ pre-treatment formulation
EP3393490A4 (en) * 2015-12-15 2019-11-20 Icahn School of Medicine at Mount Sinai METHOD FOR TREATING A CLOSED INFLAMMATORY REACTION WITH TOPOISOMERASE L-INHIBITORS
US10765881B2 (en) 2016-01-08 2020-09-08 University Of Florida Research Foundation, Inc. Magnetic particle conjugates and methods of activating cell signaling
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
RU2657545C1 (ru) * 2017-08-17 2018-06-14 Максим Артемович Абакумов Лекарственный препарат для лечения рака молочной железы
KR102141220B1 (ko) * 2017-11-30 2020-08-05 한국생산기술연구원 친수성 또는 소수성 약물을 제어하는 다공성 나노입자의 콜로이드화
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MANIPULATED EXTRACELLULAR VESICLES FOR ENHANCED RELEASE INTO TISSUE
WO2019152549A1 (en) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas
CN109374558A (zh) * 2018-12-11 2019-02-22 山东吉威医疗制品有限公司 一种无聚合物药物涂层洗脱支架体外释放度的测定方法
CN110623942B (zh) * 2019-09-30 2020-09-22 武汉大学 一种全反式维甲酸纳米药物制剂、其制备方法及应用
AU2020370342A1 (en) * 2019-10-22 2022-05-19 Otomagnetics, Inc. Lipid coated iron oxide nanoparticles for otitis media
KR20220133893A (ko) 2020-01-31 2022-10-05 매그포스 아게 자성 알콕시실란-코팅된 금속 함유 나노입자를 포함하는 페이스트
CN111554501A (zh) * 2020-04-28 2020-08-18 天津大学 磁性吸附细菌和孢子的超顺磁性镍纳米颗粒的制备方法
DE102020116859A1 (de) 2020-06-26 2021-12-30 Pharma Development Holding Gmbh Liposomen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662539B1 (fr) * 1990-05-23 1994-09-30 Centre Nat Rech Scient Procede d'obtention de supports magnetiques finement divises par modification controlee de la surface de particules precurseurs magnetiques chargees et produits obtenus.
DE4117782C2 (de) 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
US6147205A (en) * 1995-12-15 2000-11-14 Affymetrix, Inc. Photocleavable protecting groups and methods for their use
DE19614136A1 (de) * 1996-04-10 1997-10-16 Inst Neue Mat Gemein Gmbh Verfahren zur Herstellung agglomeratfreier nanoskaliger Eisenoxidteilchen mit hydrolysebeständigem Überzug
DE19624426A1 (de) * 1996-06-19 1998-01-02 Christian Bergemann Magnetische Flüssigkeiten für den Transport von diagnostisch oder therapeutisch wirksamen Substanzen
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
AU727730B2 (en) * 1997-06-25 2000-12-21 Earl P. Burke Jr. Easy mount stirrup
US6645464B1 (en) * 1998-07-30 2003-11-11 James F. Hainfeld Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
CA2384429A1 (en) * 1999-09-14 2001-03-22 Michael K. Bahr Magnetic nanoparticles having biochemical activity, method for the production thereof and their use
JP2002010471A (ja) * 2000-06-19 2002-01-11 Yazaki Corp 過電流遮断装置
JP2002090366A (ja) * 2000-09-14 2002-03-27 Rikogaku Shinkokai フェライトを固定した生体特異的親和性キャリヤとその製造方法
DE10059151C2 (de) * 2000-11-29 2003-10-16 Christoph Alexiou Magnetische Partikel zur zielgerichteten regionalen Therapie und Verwendung derselben
ATE388691T1 (de) * 2001-07-10 2008-03-15 Univ North Carolina State Träger zur freisetzung von nanopartikeln
US7074175B2 (en) * 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US20060057192A1 (en) * 2001-09-28 2006-03-16 Kane Patrick D Localized non-invasive biological modulation system
CA2476888A1 (en) 2002-02-01 2003-08-14 Vanderbilt University Targeted drug delivery methods
US20050084539A1 (en) * 2002-02-04 2005-04-21 Hiroshi Handa Organic substance having ferrite bonded thereto and process for producing the same
JP2004305055A (ja) 2003-04-04 2004-11-04 Hitachi Maxell Ltd 磁性複合粒子およびその製造方法
KR100612734B1 (ko) 2003-04-30 2006-08-18 함승주 자기성 물질 및 치료제를 생분해성 고분자로 캡슐화한자기성 나노입자를 함유하는 조성물
JP2005060221A (ja) * 2003-07-31 2005-03-10 Rikogaku Shinkokai 有機物質とフェライトとの複合材料とその製造方法
DE10350248A1 (de) 2003-10-28 2005-06-16 Magnamedics Gmbh Thermosensitive, biokompatible Polymerträger mit veränderbarer physikalischer Struktur für die Therapie, Diagnostik und Analytik
WO2005065282A2 (en) 2003-12-31 2005-07-21 The Regents Of The University Of California Remote magnetically induced treatment of cancer
WO2005070471A2 (en) * 2004-01-20 2005-08-04 Alnis Biosciences, Inc. Articles comprising magnetic material and bioactive agents
KR100604976B1 (ko) * 2004-09-03 2006-07-28 학교법인연세대학교 다작용기 리간드로 안정화된 수용성 나노입자
CA2600370A1 (en) * 2005-03-14 2006-09-14 Board Of Regents Of The University Of Texas System Bioactive fus1 peptides and nanoparticle-polypeptide complexes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2431472C2 (ru) * 2009-09-24 2011-10-20 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации Способ получения наночастиц магнетита, стабилизированных биосовместимым полимером, имеющим функциональные формильные группы

Also Published As

Publication number Publication date
EP1871423A2 (de) 2008-01-02
KR20080007323A (ko) 2008-01-18
AU2006233483B2 (en) 2009-07-16
DE112006001565A5 (de) 2008-03-27
EP1871423B1 (de) 2012-08-01
NZ561928A (en) 2010-10-29
WO2006108405A3 (de) 2007-02-01
KR20120101727A (ko) 2012-09-14
AU2006233483A1 (en) 2006-10-19
DK1871423T3 (da) 2012-10-29
US20080268061A1 (en) 2008-10-30
CA2603734A1 (en) 2006-10-19
RU2490027C9 (ru) 2013-09-27
DE102005016873A1 (de) 2006-10-19
BRPI0610220A2 (pt) 2012-09-25
RU2490027C2 (ru) 2013-08-20
WO2006108405A2 (de) 2006-10-19
CN101247836B (zh) 2013-07-10
CA2603734C (en) 2012-06-05
IL186521A0 (en) 2008-01-20
JP2008536837A (ja) 2008-09-11
JP5037490B2 (ja) 2012-09-26
ZA200708692B (en) 2009-01-28
CN101247836A (zh) 2008-08-20
ES2392346T3 (es) 2012-12-07
WO2006108405B1 (de) 2007-04-05
MX2007012670A (es) 2008-01-28
US9345768B2 (en) 2016-05-24
KR20130098441A (ko) 2013-09-04
IL186521A (en) 2013-03-24
EP1871423B9 (de) 2014-09-10

Similar Documents

Publication Publication Date Title
RU2007141588A (ru) Наночастица, и на ее основе инфузионный раствор и фармацевтическая композици
RU2480201C2 (ru) Способ профилактики и/или лечения раковых заболеваний
Jiang et al. Recent advances of halloysite nanotubes in biomedical applications
Kanwar et al. Neurological disorders and therapeutics targeted to surmount the blood–brain barrier
RU2008130167A (ru) Система-носитель на протеиновой основе для преодоления резистентности опухолевых клеток
JP5717446B2 (ja) ナノ粒子、ナノ粒子の製造方法及びナノ粒子を含む医薬組成物
Arakelova et al. In vitro and in vivo anticancer activity of nanosize zinc oxide composites of doxorubicin
Gao et al. Loading and releasing behavior of selenium and doxorubicin hydrochloride in hydroxyapatite with different morphologies
Ren et al. Current trends on repurposing and pharmacological enhancement of andrographolide
JP2010509241A5 (ru)
RU2610170C1 (ru) Наноматериал для направленной доставки противоопухолевых препаратов и противоопухолевый препарат на его основе
Huang et al. A DNA nano-train carrying a predefined drug combination for cancer therapy
Huang et al. Neutrophil-targeted nanomedicine delivery systems: therapeutic applications and future perspectives in sepsis management
Jain et al. Therapeutically important bioactive compounds derived from fungal origin
Siddiqui et al. Zinc oxide nanoparticles: Mechanism (s) of cell death induced in human epidermoid larynx cell line (HEp-2)
KR101780272B1 (ko) siRNA의 동시 사일런싱이 가능한 RNA 전사체-DNA 접합체 하이브리드 및 이의 용도
Sinha et al. ROLE OF GREEN SILVER NANOPARTICLES IN SUPPRESSING VARIOUS HUMAN PATHOGENESIS.
AU2011236018B2 (en) Method for carrying therapeutic substances into cells
US20090041837A1 (en) Aptamers utilized as targeting agents for pharmaceutical compounds used in the treatment of cancer and other diseases
CN114848837A (zh) 一种多肽药物偶联体与核酸药物自组装成纳米颗粒及其应用
MX2008008125A (es) Sistema de soporte basado en proteinas para vencer la resistencia de las celulas tumorales

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100216

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20101216

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20120206

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20120523

TH4A Reissue of patent specification
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160413